BACKGROUND: Pancreatic cancer cells express different mutations that increase the aggressiveness and confer resistance to conventional chemotherapy and radiotherapy. Molecules that selectively bind and inhibit these mutations are effective in other solid tumors and are now emerging as a complementary therapy in pancreatic cancer. The objective of this review is to describe the effect of drugs that inhibit specific mutations present in pancreatic cancer with special emphasis on clinical trials. DATA SOURCES: We reviewed the English-language literature (MedLine) addressing the role of drugs that target mutations present in pancreatic cancer. Both preclinical and clinical studies were included. CONCLUSIONS: Preclinical evidence supports the combination of conventional approved therapies plus drugs that block epidermal growth factor receptor and vascular growth endothelial factor or induce apoptosis. However, most of the current clinical evidence is limited to small phase I trials evaluating the toxicity and safety of these regimens. The results of additional randomized trials that are still undergoing will clarify the role of these drugs in pancreatic cancer.
BACKGROUND:Pancreatic cancer cells express different mutations that increase the aggressiveness and confer resistance to conventional chemotherapy and radiotherapy. Molecules that selectively bind and inhibit these mutations are effective in other solid tumors and are now emerging as a complementary therapy in pancreatic cancer. The objective of this review is to describe the effect of drugs that inhibit specific mutations present in pancreatic cancer with special emphasis on clinical trials. DATA SOURCES: We reviewed the English-language literature (MedLine) addressing the role of drugs that target mutations present in pancreatic cancer. Both preclinical and clinical studies were included. CONCLUSIONS: Preclinical evidence supports the combination of conventional approved therapies plus drugs that block epidermal growth factor receptor and vascular growth endothelial factor or induce apoptosis. However, most of the current clinical evidence is limited to small phase I trials evaluating the toxicity and safety of these regimens. The results of additional randomized trials that are still undergoing will clarify the role of these drugs in pancreatic cancer.
Authors: Leo Christopher DeRosier; Zhi-Qiang Huang; Jeffrey C Sellers; Donald J Buchsbaum; Selwyn M Vickers Journal: J Gastrointest Surg Date: 2006-11 Impact factor: 3.452
Authors: Joan Maurel; Marta Martin-Richard; Carlos Conill; Marcelo Sánchez; Lourdes Petriz; Angels Ginès; Rosa Miquel; Rosa Gallego; Rosana Cajal; Carmen Ayuso; Salvador Navarro; Maribel Marmol; Cristina Nadal; Josep Maria Augé; Laureano Fernández-Cruz; Pere Gascón Journal: Int J Radiat Oncol Biol Phys Date: 2006-09-11 Impact factor: 7.038
Authors: Ching-Wei D Tzeng; Andrey Frolov; Natalya Frolova; Nirag C Jhala; J Harrison Howard; Donald J Buchsbaum; Selwyn M Vickers; Martin J Heslin; J Pablo Arnoletti Journal: Surgery Date: 2007-01-22 Impact factor: 3.982
Authors: Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Michael J Thun Journal: CA Cancer J Clin Date: 2007 Jan-Feb Impact factor: 508.702
Authors: Israel Vlodavsky; Phillip Beckhove; Immanuel Lerner; Claudio Pisano; Amichai Meirovitz; Neta Ilan; Michael Elkin Journal: Cancer Microenviron Date: 2011-08-03
Authors: Anna M Czarnecka; Piotr Korzeń; Anna Nowak-Dement; Wojciech Kukwa; Jan Korniluk; Cezary Szczylik Journal: Oncol Lett Date: 2015-12-07 Impact factor: 2.967
Authors: Lei Duan; Guoguang Ying; Brian Danzer; Ricardo E Perez; Zia Shariat-Madar; Victor V Levenson; Carl G Maki Journal: J Biol Chem Date: 2014-06-16 Impact factor: 5.157